- Previous Close
8.350 - Open
8.200 - Bid 7.830 x --
- Ask 7.890 x --
- Day's Range
7.660 - 8.350 - 52 Week Range
2.710 - 8.980 - Volume
7,622,294 - Avg. Volume
4,889,421 - Market Cap (intraday)
4.884B - Beta (5Y Monthly) 1.28
- PE Ratio (TTM)
195.75 - EPS (TTM)
0.040 - Earnings Date Mar 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.95
Abbisko Cayman Limited engages in the discovering and developing small molecule oncology therapies in China. The company develops pimicotinib, which is in Phase III clinical trial for treatment of tenosynovial giant cell tumor; Irpagratinib that is in Phase II clinical trial for treatment of liver cancer; Fexagratinib, which is in Phase II clinical trial for the treatment of urothelial carcinoma; ABSK043 that is in Phase I clinical trial for treatment of multiple tumors; ABSK061, ABSK121, and ABSK051, which is in Phase I clinical trial for treatment of solid tumors; ABSK112 that is in Phase I of clinical trial for treatment of non-small cell lung cancer; ABSK012, which is in Phase I clinical trial for treatment of soft tissue sarcoma. It is involved in technical services and consultation. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
www.abbisko.comRecent News: 2256.HK
View MorePerformance Overview: 2256.HK
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2256.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2256.HK
View MoreValuation Measures
Market Cap
5.21B
Enterprise Value
3.13B
Trailing P/E
194.76
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.04
Price/Book (mrq)
2.48
Enterprise Value/Revenue
5.80
Enterprise Value/EBITDA
36.72
Financial Highlights
Profitability and Income Statement
Profit Margin
5.62%
Return on Assets (ttm)
-0.64%
Return on Equity (ttm)
1.44%
Revenue (ttm)
503.99M
Net Income Avi to Common (ttm)
28.3M
Diluted EPS (ttm)
0.040
Balance Sheet and Cash Flow
Total Cash (mrq)
2.01B
Total Debt/Equity (mrq)
1.24%
Levered Free Cash Flow (ttm)
--